The role of patient-reported outcomes in health technology assessments: global practices and future implications
Barriers to the use of PRO data for evaluations require further efforts from all relevant stakeholders to promote PRO incorporation in payer decision-making.
Authors
- Olivier Chassany (ORCID: https://orcid.org/0000-0001-8361-5809)
- J. García–Sánchez (ORCID: https://orcid.org/0000-0002-7772-5718)
- Calvin N. Ho (ORCID: https://orcid.org/0000-0002-3360-9651)
- Billie Pettersson
- James C. Ryan (ORCID: https://orcid.org/0000-0002-1101-3785)
- Livia Lai
- Jill A. Bell
- Nenad Medic (ORCID: https://orcid.org/0009-0002-6047-7719)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Université Paris Cité (FR)
- IQVIA (United Kingdom) (GB)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Italy) (IT)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1080/14737167.2025.2603946
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00